» Articles » PMID: 33596280

Improving the Genistein Oral Bioavailability Its Formulation into the Metal-organic Framework MIL-100(Fe)

Overview
Journal J Mater Chem B
Date 2021 Feb 17
PMID 33596280
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the interesting chemopreventive, antioxidant and antiangiogenic effects of the natural bioflavonoid genistein (GEN), its low aqueous solubility and bioavailability make it necessary to administer it using a suitable drug carrier system. Nanometric porous metal-organic frameworks (nanoMOFs) are appealing systems for drug delivery. Particularly, mesoporous MIL-100(Fe) possesses a variety of interesting features related to its composition and structure, which make it an excellent candidate to be used as a drug nanocarrier (highly porous, biocompatible, can be synthesized as homogenous and stable nanoparticles (NPs), etc.). In this study, GEN was entrapped via simple impregnation in MIL-100 NPs achieving remarkable drug loading (27.1 wt%). A combination of experimental and computing techniques was used to achieve a deep understanding of the encapsulation of GEN in MIL-100 nanoMOF. Subsequently, GEN delivery studies were carried out under simulated physiological conditions, showing on the whole a sustained GEN release for 3 days. Initial pharmacokinetic and biodistribution studies were also carried out upon the oral administration of the GEN@MIL-100 NPs in a mouse model, evidencing a higher bioavailability and showing that this oral nanoformulation appears to be very promising. To the best of our knowledge, the GEN-loaded MIL-100 will be the first antitumor oral formulation based on nanoMOFs studied in vivo, and paves the way to the efficient delivery of nontoxic antitumorals via a convenient oral route.

Citing Articles

The Role of Genistein in Type 2 Diabetes and Beyond: Mechanisms and Therapeutic Potential.

Kciuk M, Kruczkowska W, Wanke K, Galeziewska J, Kolat D, Mujwar S Molecules. 2025; 30(5).

PMID: 40076293 PMC: 11901726. DOI: 10.3390/molecules30051068.


Recent advancements in genistein nanocarrier systems for effective cancer management.

Arora D, Vanshita , Bhati H, Bansal K Med Oncol. 2025; 42(4):101.

PMID: 40072692 DOI: 10.1007/s12032-025-02649-w.


Metal-organic frameworks in oral drug delivery.

Raza A, Wu W Asian J Pharm Sci. 2024; 19(5):100951.

PMID: 39493807 PMC: 11530798. DOI: 10.1016/j.ajps.2024.100951.


Articulating the Pharmacological and Nanotechnological Aspects of Genistein: Current and Future Prospectives.

Bansal K, Singh V, Mishra S, Bajpai M Curr Pharm Biotechnol. 2024; 25(7):807-824.

PMID: 38902930 DOI: 10.2174/0113892010265344230919170611.


Recent progress and challenges of MOF-based nanocomposites in bioimaging, biosensing and biocarriers for drug delivery.

Nguyen N, Nguyen T, Ge S, Liew R, Nguyen D, Tran T Nanoscale Adv. 2024; 6(7):1800-1821.

PMID: 38545292 PMC: 10964756. DOI: 10.1039/d3na01075a.